The Wockhardt Group, previously a prominent player in the pharmaceutical industry, is facing financial difficulties. With mounting debts and a struggling business, the group's significant assets are now being put up for grabs. This sudden shift in fortunes has sent shockwaves through the industry, leaving many observers. It remains unknown who wil